Lille (France), Cambridge (Massachusetts, United States), February 23rd, 2012 – GENFIT (Alternext: ALGFT;
ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development,
focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today
announces the extension of patent protection for GFT505, its leading drug candidate, to major worldwide
Following on from GFT505 patents already delivered in the United States, Europe, China, Russia, and Australia,
the Canadian, Japanese, and Indian patent offices have granted new patents to GENFIT. All these new patents
concern GFT505, as well as a series of structural variants, their synthesis procedures, and their pharmaceutical
use in the field of cardiometabolic diseases, as well as their combination with existing medicines.
This patent cover also spans the use of GFT505 in certain hepatic complications of pre-diabetes and diabetes,
including NASH*, the major therapeutic indication for GFT505. This therapeutic position was recently
strengthened by the GFT505-210-6 study of insulin-resistant patients, that met all its primary and secondary
efficacy endpoints and demonstrated the safety of use of GFT505.
These new patents bring the total number of GENFIT’s international patents to 217, of which 152 cover
Jean-François Mouney, Chairman and Chief Executive Officer of GENFIT, declared: « Over the years GENFIT
has created an extensive patent cover for GFT505, comprising a wide range of clinical and pharmaceutical data
of strategic importance for its future commercialization by a partner. In parallel, the Company continues to
pursue its activities in technological and clinical development, notably in the field of biomarkers. These
developments will result in additional patent applications in 2012, and should further strengthen this strategical
*About NAFLD and NASH:
NAFLD (non-alcoholic fatty liver disease) and in particular NASH (non-alcoholic steatohepatitis) are serious liver
diseases that can lead to cirrhosis and liver cancer. The development of NAFLD/NASH is associated with the
diabetic pathophysiological process. NAFLD is believed to affect between 80 and 100% of diabetic patients, and
progresses to chronic liver disease (NASH) in 20-50% of cases. Mortality due to liver disease is thus 2-3-fold
higher in the diabetic population than in the overall population. The NASH market was estimated at 615 $M in
2010 and should reach 2,008 $M in 2018.
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in
therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive
solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in
partnership with leading pharmaceutical companies (SANOFI, SERVIER, …), to address these major public health
concerns and their unmet medical needs.
GENFIT’s research programs have resulted in the creation of a rich and diversified pipeline of drug candidates
at different stages of development, including GENFIT’s lead proprietary compound, GFT505, that is currently in
With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees.
GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN:
Jean-François Mouney – CEO & Chairman of the Management Board
+33 (0)3 2016 4000
MILESTONES – Press Relations
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – email@example.com